Literature DB >> 23896479

The FDA reboot of antibiotic development.

David M Shlaes1, Dan Sahm, Carol Opiela, Brad Spellberg.   

Abstract

Mesh：

Substances：

Year:  2013        PMID： 23896479      PMCID： PMC3811409          DOI： 10.1128/AAC.01277-13

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


× No keyword cloud information.
  15 in total

1.  The United States Food and Drug Administration and the end of antibiotics.

Authors:  David M Shlaes; Robert C Moellering
Journal:  Clin Infect Dis       Date:  2002-02-01       Impact factor: 9.079

2.  Acute bacterial skin and skin structure infection trials: the bad is the enemy of the good.

Authors:  Brad Spellberg
Journal:  Clin Infect Dis       Date:  2011-10-25       Impact factor: 9.079

3.  The critical impact of time discounting on economic incentives to overcome the antibiotic market failure.

Authors:  Brad Spellberg; Priya Sharma; John H Rex
Journal:  Nat Rev Drug Discov       Date:  2012-02-01       Impact factor: 84.694

4.  Sulphanilamide in the Treatment of Erysipelas.

Authors:  W R Snodgrass; T Anderson
Journal:  Br Med J       Date:  1937-12-11

5.  Prontosil in Erysipelas.

Authors:  W R Snodgrass; T Anderson
Journal:  Br Med J       Date:  1937-07-17

6.  Fix the antibiotics pipeline.

Authors:  Matthew A Cooper; David Shlaes
Journal:  Nature       Date:  2011-04-07       Impact factor: 49.962

7.  A comprehensive regulatory framework to address the unmet need for new antibacterial treatments.

Authors:  John H Rex; Barry I Eisenstein; Jeff Alder; Mark Goldberger; Robert Meyer; Aaron Dane; Ian Friedland; Charles Knirsch; Wendy R Sanhai; John Tomayko; Cindy Lancaster; Jennifer Jackson
Journal:  Lancet Infect Dis       Date:  2013-01-15       Impact factor: 25.071

8.  Placebo-controlled trials and active-control trials in the evaluation of new treatments. Part 1: ethical and scientific issues.

Authors:  R Temple; S S Ellenberg
Journal:  Ann Intern Med       Date:  2000-09-19       Impact factor: 25.391

9.  The future of antibiotics and resistance.

Authors:  Brad Spellberg; John G Bartlett; David N Gilbert
Journal:  N Engl J Med       Date:  2013-01-24       Impact factor: 91.245

10.  Vital signs: carbapenem-resistant Enterobacteriaceae.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2013-03-08       Impact factor: 17.586
View more
  47 in total

1.  Systematic Review and Meta-Analysis To Estimate Antibacterial Treatment Effect in Acute Bacterial Skin and Skin Structure Infection.

Authors:  Jordan E Cates; Fanny S Mitrani-Gold; Gang Li; Linda M Mundy
Journal:  Antimicrob Agents Chemother       Date:  2015-05-18       Impact factor: 5.191

Review 2.  Novel approaches are needed to develop tomorrow's antibacterial therapies.

Authors:  Brad Spellberg; John Bartlett; Rich Wunderink; David N Gilbert
Journal:  Am J Respir Crit Care Med       Date:  2015-01-15       Impact factor: 21.405

3.  The political and ethical challenge of multi-drug resistant tuberculosis.

Authors:  Chris Degeling; Christopher Mayes; Wendy Lipworth; Ian Kerridge; Ross Upshur
Journal:  J Bioeth Inq       Date:  2015-01-29       Impact factor: 1.352

4.  Antibiotics Resistance: When the Armamentarium Gets to the Verge of Being Empty.

Authors:  Abdullah Balkhair
Journal:  Oman Med J       Date:  2017-07

5.  Combination Therapy for Extreme Drug-Resistant Acinetobacter baumannii: Ready for Prime Time?

Authors:  Brad Spellberg; Robert A Bonomo
Journal:  Crit Care Med       Date:  2015-06       Impact factor: 7.598

6.  The future of antibiotics and resistance: a tribute to a career of leadership by John Bartlett.

Authors:  Brad Spellberg; David N Gilbert
Journal:  Clin Infect Dis       Date:  2014-09-15       Impact factor: 9.079

7.  3-Substituted Biquinolinium Inhibitors of AraC Family Transcriptional Activator VirF from S. flexneri Obtained Through In Situ Chemical Ionization of 3,4-Disubstituted Dihydroquinolines.

Authors:  Prashi Jain; Jiaqin Li; Patrick Porubsky; Benjamin Neuenswander; Susan M Egan; Jeffrey Aubé; Steven Rogers
Journal:  RSC Adv       Date:  2014-01-01       Impact factor: 3.361

Review 8.  Emerging drugs and vaccines for candidemia.

Authors:  Brad Moriyama; Lori A Gordon; Matthew McCarthy; Stacey A Henning; Thomas J Walsh; Scott R Penzak
Journal:  Mycoses       Date:  2014-10-08       Impact factor: 4.377

9.  The Capsular Polysaccharide of Acinetobacter baumannii Is an Obstacle for Therapeutic Passive Immunization Strategies.

Authors:  Shun Xin Wang-Lin; Ruth Olson; Janet M Beanan; Ulrike MacDonald; Joseph P Balthasar; Thomas A Russo
Journal:  Infect Immun       Date:  2017-11-17       Impact factor: 3.441

10.  Structure-Activity Relationships of the MEPicides: N-Acyl and O-Linked Analogs of FR900098 as Inhibitors of Dxr from Mycobacterium tuberculosis and Yersinia pestis.

Authors:  Géraldine San Jose; Emily R Jackson; Amanda Haymond; Chinchu Johny; Rachel L Edwards; Xu Wang; R Carl Brothers; Emma K Edelstein; Audrey R Odom; Helena I Boshoff; Robin D Couch; Cynthia S Dowd
Journal:  ACS Infect Dis       Date:  2016-10-12       Impact factor: 5.084
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.